Careers  |   Log In  |   Register  |   Welcome Center  |   Twitter Google Plus
The Doctor's Channel
Recent Posts
The trial revealed a linear correlation between higher tumor burden and anti-PD1 and anti-programmed death ligand (PD-L1) checkpoint inhibitors, explained as the immune system responding to reactivation.